IMR Press / FBL / Volume 7 / Issue 5 / DOI: 10.2741/salit

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Ins and outs of clinical trials with peptide-based vaccines
Show Less
1 Cancer Immunology Program, Cardinal Bernardin Cancer Center, Loyola University Chicago 2160 S. First Ave, Maywood, IL 60153, USA

Academic Editor: Jagannadha Sastry

Front. Biosci. (Landmark Ed) 2002, 7(5), 204–213; https://doi.org/10.2741/salit
Published: 1 May 2002
(This article belongs to the Special Issue Peptide-based vaccines and therapeutics against immune disorders)
Abstract

Peptides are the smallest antigenic components that are recognized by T cells when presented in MHC molecules on the cell surface. After the identification of peptides from tumor associated and tumor specific antigens, the exploration of the use of peptides in immunotherapy of cancer was instigated. From initial exploration of peptide-mediated induction of immune responses in mice, the peptide based vaccines have evolved to clinical testing in cancer patients. Many different clinical trials have been performed to address the ability of peptide-based vaccines to induce both clinical and immunological responses in patients. This review will provide an overview of the results of the majority of the clinical trials with peptide-based vaccines directed against various antigens in patients with solid tumors.

Keywords
Clinical Trial
Peptide
Vaccination
Cancer
Review
Share
Back to top